Proteasome inhibitor drugs on the rise

Cancer Res. 2006 Aug 15;66(16):7840-2. doi: 10.1158/0008-5472.CAN-06-2033.


In May 2003, the U.S. Food and Drug Administration granted the proteasome inhibitor bortezomib (Velcade) fast-track status for the treatment of multiple myeloma. This landmark represented the first approval of a drug targeting the ubiquitin-proteasome system (UPS) for any indication. More recently, at the AACR Special Conference "Ubiquitin and Cancer: From Molecular Targets and Mechanisms to the Clinic" (Orlando, FL, January 18-22, 2006), it became evident that drug discovery in the UPS is experiencing another round of great excitement. The reason--new clinical applications found for bortezomib, along with the promised success of new types of proteasome inhibitors reaching the clinic.

Publication types

  • Congress

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Boronic Acids / therapeutic use
  • Bortezomib
  • Humans
  • Multiple Myeloma / drug therapy
  • Proteasome Inhibitors*
  • Pyrazines / therapeutic use
  • Ubiquitin / metabolism
  • United States
  • United States Food and Drug Administration


  • Antineoplastic Agents
  • Boronic Acids
  • Proteasome Inhibitors
  • Pyrazines
  • Ubiquitin
  • Bortezomib